Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06202274 · ClinicalTrials.gov registry record · NA
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
A NA study of Acne and Wrinkle, sponsored by Candela Corporation.
- Active
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 3
- Study locations
NCT06202274: Active NA study of Acne and Wrinkle, sponsored by Candela Corporation.
NCT06202274 is a NA study of Acne and Wrinkle that is active but no longer recruiting, run by Candela Corporation. The registered enrollment target is 500 participants, above the 123-participant average among 26 other Acne trials with a reported enrollment target (307% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06202274, a NA study of Acne and Wrinkle, is active but no longer recruiting, sponsored by Candela Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a non-randomized, multi-center, open-label, prospective clinical study evaluating the clinical treatment with Candela Medical Technology.
Primary Outcome
Subject assessment of treatment discomfort/pain immediately post-treatment via Numerical Rating Scale (NRS). Subjects will be presented a horizontal line scale and asked to make a mark along the scale. Subjects will be asked to rate pain from 0 to 10, with 0 equaling no pain and 10 equaling the worst possible pain. A number is obtained by measuring up to the point the participant has indicated.
Conditions Studied
Interventions
- DEVICE Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE
Study Locations (3)
Florida
- Center for Morden Aesthetic Medicine - Jacksonville
Massachusetts
- Candela Institue for Excellence - Marlborough
Other
- Yokneam Candela Clinic - Yokneam Illit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2029-10-04 |
| Phase | NA |
What the registry record for NCT06202274 still lists
NCT06202274 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 123-participant average among 26 other Acne trials with a reported enrollment target (307% higher).
The record links to 7 conditions, with Acne appearing as the primary indexed condition, and to 1 intervention - of which Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE is the first listed.
NCT06202274 reports a single indexed study location in Florida, Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT06202274 about?
NCT06202274 is a clinical study titled "Clinical Study to Evaluate the Safety and Efficacy of Candela Technology". This is a non-randomized, multi-center, open-label, prospective clinical study evaluating the clinical treatment with Candela Medical Technology.
What is the current status of trial NCT06202274?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2023-10-04. Estimated completion is 2029-10-04.
What conditions does trial NCT06202274 study?
This clinical trial studies the following conditions: Acne, Wrinkle, Scars, Tattoo Removal, Skin Conditions.
What interventions are being tested in trial NCT06202274?
The interventions under investigation include: Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE (DEVICE).
Who is sponsoring clinical trial NCT06202274?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06202274 being conducted?
This trial has 3 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06202274's enrollment target sits among peer trials
500 2nd of 26 the highest of 26 other Acne trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation
COMPLETED · NA
-
An Exploratory Investigation of a Male Focused Skincare Supplement
COMPLETED · NA
-
An Exploratory Investigation of a Novel Skincare Regimen
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI